Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL): Outcomes of patients treated in salvage one with a long duration of first remission.

Authors

Hagop Kantarjian

Hagop M. Kantarjian

The University of Texas MD Anderson Cancer Center, Houston, TX

Hagop M. Kantarjian , Matthias Stelljes , Anjali S. Advani , Daniel J. DeAngelo , David I. Marks , Wendy Stock , Susan Mary O'Brien , Ryan Daniel Cassaday , Tao Wang , Alexander Neuhof , Erik Vandendries , Elias Jabbour

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT01564784

Citation

J Clin Oncol 37, 2019 (suppl; abstr 7029)

DOI

10.1200/JCO.2019.37.15_suppl.7029

Abstract #

7029

Poster Bd #

404

Abstract Disclosures